Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research. This webinar will provide practical insights into how lentiviral, AAV, and other delivery systems are used alongside CRISPR technologies to create targeted genetic modifications in mammalian cells.
The session will cover the development of engineered disease models, including cancer models and genetic knockouts, along with strategies for validating edited cell systems and advancing from in vitro studies to in vivo applications. Through real-world examples, attendees will gain a clearer understanding of complete gene editing workflows, from experimental design to practical application.
Join this session to understand how CRISPR and viral vector technologies are enabling more advanced and translationally relevant disease models for biomedical research.
Speaker
Miguel Mantilla
Head of Business Development | abm
Miguel Mantilla, MBA, PhD, is a biotechnology executive specializing in translational life sciences, gene modulation technologies, and advanced cellular engineering. He currently serves as Head of Business Development (EMEA) at Applied Biological Materials (abm), where he leads strategic expansion across Europe, the Middle East, and Latin America, focusing on the deployment of CRISPR-based systems, viral vector platforms, and engineered cell models into academic and biopharma research environments. He holds an MBA from Esden Business School, an MSc in Molecular Biology from the University of Buenos Aires, and a PhD in Neuroscience from the Weizmann Institute of Science, with a research background rooted in neurobiology, systems neuroscience, and cellular signaling. His work integrates molecular and cellular neuroscience with industrial biotechnology, with emphasis on RNA biology, gene regulation, and platform technologies enabling functional disease modelling and translational research.
Key Learning Objectives
- Use of lentiviral, AAV, and other delivery systems for gene editing applications
- How CRISPR is used to turn genes on or off and create targeted genetic modifications
- Development of disease models including cancer models and genetic knockouts
- Validation of engineered cell models and progression from in vitro to in vivo systems
- Practical framework for designing and executing complete gene editing workflows from concept to application
Watch Now: Viral Vectors & CRISPR for Building Disease Models
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- June 12, 2026 · 03:00 – 04:00 pm IST
- Miguel Mantilla, abm
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and you'll go straight to the recording — we'll also email you the link.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar April 17, 2026Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated.
View Webinar September 19, 20253D Cell Culture & Organoids: Bridging Basic Research and Clinical Translation
The landscape of biomedical research is rapidly evolving with the advent of advanced 3D cell culture and organoid technologies. While traditional 2D systems have long been the foundation of experimental biology, they often lack the physiological relevance needed for accurate translational outcomes.
View Webinar